A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety and tolerability of single oral ascending doses of E6007 in healthy subjects.

Phase 1

Eisai Inc.